Testing has demonstrated Betadine's strong in-vitro virucidal activity, killing 99.99% of the SARS-CoV-2 virus in 30 seconds. The products subjected to testing were: Betadine antiseptic products, namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle and Mouthwash (1.0% PVP-I) and Throat Spray (0.45% PVP-I).
The research has been published in the respected Infectious Disease and Therapy Journal on 08 July 2020.
The study conducted at Duke-NUS is complemented by Laboratory testing completed at the Tropical Infectious Diseases Research and Education Center (TIDREC) at the University of Malaya, Malaysia, that also demonstrated strong in-vitro virucidal activity, with the tested product Betadine Gargle and Mouthwash (1.0% PVP-I) killing 99.99% of the SARS-CoV-2 virus in 15 seconds.
The TIDREC research has been accepted by the British Dental Journal and was published as a Letter on 26 June 2020. The journal is published by Springer Nature on behalf of the British Dental Association.
Previously, Betadine antiseptic products containing povidone iodine (PVP-I) have been proven effective in vitro against a wide range of viruses, including coronaviruses that have caused major outbreaks such as Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome.
The Betadine antiseptic range contains Povidone-iodine (PVP-I), which is highly effective against a wide range of microorganisms, including bacteria, viruses and fungi and is typically used in hospitals.
Mundipharma's independent associated companies are privately owned entities covering the world's pharmaceutical markets.
Mundipharma offers novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
The Betadine range of products have been trusted by hospitals and consumers around the world for over 60 years to prevent and treat infections.
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
INOVIO's INO-3107 Biologics License Application accepted by US FDA
ABL Bio receives upfront payment and equity investment from Eli Lilly
CARsgen Therapeutics submits two IND applications for CT0596 to Chinese regulator
Repare Therapeutics sells RP-3467 asset to Gilead Sciences for up to USD30m
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
NeuroSense Therapeutics completes safety evaluation of PrimeC in Alzheimer's Phase 2 study
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development